Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 10/20 | 0.35 |
| ▸ | CNR2 | P34972 | 10/20 | 0.35 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23620717 | 0.77 | HPGD (0.43) | — | |
| SCHEMBL1476095 | 0.77 | MEP1B (0.34) | MEP1BCES2CES1 | |
| SCHEMBL9842861 | 0.75 | CRBN (0.36) | CNR1CNR2CRBNKDM4EPKM | |
| SCHEMBL5177356 | 0.74 | MEN1 (0.32) | — | |
| SCHEMBL6167819 | 0.72 | KEAP1 (0.45) | CNR1CNR2PDE4B | |
| SCHEMBL116279 | 0.70 | MAPT (0.36) | MEP1BKDM4ECES2CES1 | |
| SCHEMBL141511 | 0.70 | MAPT (0.36) | MEP1BKDM4ECES2CES1 | |
| SCHEMBL6233921 | 0.70 | MAPT (0.36) | MEP1BKDM4ECES2CES1 | |
| SCHEMBL27581775 | 0.69 | MEP1B (0.43) | MEP1BCES2CES1 | |
| SCHEMBL10423017 | 0.68 | ALDH1A1 (0.40) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120058989-A1 | ANTIBACTERIAL FLUOROQUINOLONE ANALOGS | ACHAOGEN, INC. (US) | 2012-03-08 | — | — | US | disclosed |
| EP-2250171-A2 | ANTIBACTERIAL FLUOROQUINOLONE ANALOGS | Achaogen, Inc. (US) | 2010-11-17 | — | — | EP | disclosed |
| WO-2009137130-A2 | ANTIBACTERIAL FLUOROQUINOLONE ANALOGS | ACHAOGEN, INC. (US) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058989-A1 | ANTIBACTERIAL FLUOROQUINOLONE ANALOGS | RECQL, BLVRB, NQO2 | CNR1 2761/4885CNR2 3963/4885MEP1B 2142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.